bioRxiv

Protein levels alter drug sensitivity in lab-grown human cells

Cells still stopped dividing after radiation, but protein levels changed their secreted signals and sensitivity to a drug that kills senescent cells.

A large intact fibroblast sits among secreted droplets beneath smaller cells, including a dying cell with a shrunken nucleus and scattered fragments.

Our read

Mechanisms
Studied:
Preprint: experiments in normal human fibroblasts, against cells with high TIP60
What changed:
Cells with low TIP60 were completely resistant to ABT-263; cells with high TIP60 were modestly more sensitive
The catch:
Reported drug responses cover ABT-263 alone, not other senolytic drugs
In the record:
The 4th paper on KAT5 with results in people; 11 on record in all.

Editor of record: Boris Djordjevic · AgingResearch.News

Follow @agingbrief

Normal human fibroblasts, cells that support connective tissue, received a single 10-gray dose of ionizing radiation in laboratory experiments on senescence, a state in which cells stop dividing. Levels of TIP60, a protein that modifies DNA packaging, affected the cells’ production of secreted substances and their sensitivity to apoptosis, a form of programmed cell death. TIP60 was not required for the halt in cell division.

Cells with low TIP60 had more MCL-1, a protein that prevents apoptosis, and were completely resistant to ABT-263, a drug that kills senescent cells. Cells with high TIP60 were modestly more sensitive to the drug.

Why it matters

Targeting senescent cells is an approach studied in aging research. The authors suggested that also inhibiting MCL-1 could be a rational addition when TIP60 levels are low.

Caveats

Experiments in radiation-exposed human fibroblasts cannot show how senescent cells in people would respond. The work is a preprint and has not been peer-reviewed.

Where the evidence stands

Navitoclax

Cells, mice and humans: replicated by independent labs. Worms or flies: nothing yet.
  • 82 independent labs in 20 countries
  • 4 findings against
  • 28 trials, 10 with no results posted
  • Funders: National Institutes of Health and others
  • 41 of 275 findings with company ties
  • 17 of 28 trials sponsored by its developers

Apoptosis

Cells, worms or flies, mice and humans: replicated by independent labs.
  • 620 independent labs in 59 countries
  • 141 findings against
  • Funders: National Natural Science Foundation of China and others
  • 62 of 1,814 findings with company ties

Comments

Be the first to comment.